Contact No: +91-8826373757 | +91-8826859373 | 011-25052216
Email: rakesh.its@gmail.com | editor@innovativepublication.com
  • Indexing List

IP International Journal of Comprehensive and Advanced Pharmacology


Evaluation of avena sativa seeds extract as cardioprotective agent in rats


Full Text PDF Share on Facebook Share on Twitter


Article Type : Research Article

Author Details: Harmanpreet Kaur,K G. Singhal,V K. Gupta,Monika Gupta*

Volume : 4

Issue : 2

Online ISSN : 2456-9542

Print ISSN : 2581-5555

Article First Page : 39

Article End Page : 47


Abstract

The present study was undertaken to evaluate the cardioprotective effect of Avena Sativa Linn. seeds in rats. Isoproterenol at a dose level 5.25 on 11th day and 8.5 mg/kg s.c. on 12th day had been utilized to induce Myocardial infarction in Rats. The animals were pretreated with ASSAE (125, 250 and 500 mg/kg/day, oral) for period of 10 days and Isoproterenol (ISO) was injected on 11th and 12th day. The blood was collected after 24 hours through retero-orbital plexus for the estimation of biochemical parameters. The histopathological studies were also performed. The infarct size in heart was evaluated using TTC staining. The administration of ASSAE significantly increased GSH level and lowered the level of the alkaline phosphatase (ALP), lactate dehydrogenase (LDH), TBARS levels, creatinine phosphokinase (CK-MB) as well as significantly changed haemodynamic parameters in the Isoproterenol Induced myocardial necrosis. The integrity of the myocardial cell membrane and inflammatory cell infiltration and reduced muscle separation were promptly improved in the histopathological studies of the ISO-induced myocardium. These results presented here clearly demonstrated the cardioprotective activity of the ASSAE against Isoproterenol induced myocardial infarction in rats. The effect of climatic conditions on the chemical constituents responsible for the cardioprotective activity can also be explored.

Keywords: Avena sativa, Cardioprotective agents, Isoprotenenol, Myocardial infarction.

Doi :-https://doi.org/10.18231/j.ijcaap.2019.009